SFOSF Stock Chart & Stats
$2.78
-$0.10(-5.62%)
At close: 4:00 PM EST
$2.78
-$0.10(-5.62%)
Day’s Range― - ―
52-Week Range$1.94 - $3.50
Previous CloseN/A
Volume200.00
Average Volume (3M)46.00
Market Cap
$8.68B
Enterprise Value$84.21K
Total Cash (Recent Filing)$15.29B
Total Debt (Recent Filing)$31.86B
Price to Earnings (P/E)18.8
Beta-0.02
Next Earnings
Aug 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield1.76%
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume20
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.22Price Target Upside15.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.19
Revenue Forecast (FY)$5.57B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelFosun Pharma's multi-segment model (manufacturing, distribution, and healthcare services) creates durable revenue diversification across product sales, distribution margins and service fees. This reduces single-product concentration risk and supports steadier cash flows across cycles.
Revenue Rebound With Solid MarginsA strong TTM revenue rebound combined with ~49% gross margin and ~8.1% net margin indicates improved commercial execution and product mix recovery. Sustained revenue traction with healthy gross margins supports long-term profitability and reinvestment capacity.
Operating Cash Flow RecoveryOperating cash flow turned solidly positive and free cash flow recovered to positive in recent periods, reducing acute liquidity pressure. Restored cash generation improves ability to fund capex, service debt and support strategic investments without relying solely on external financing.
Bears Say
Weak Cash ConversionEarnings are not converting efficiently into cash: FCF at ~24% of net income and a volatile FCF history mean reported profits may overstate available internally generated resources. This limits durable capacity for dividends, buybacks or large organic investments without raising external funding.
Moderate LeverageA debt-to-equity ratio near 0.75 implies meaningful financial leverage. While manageable in stable conditions, this level reduces flexibility and raises interest service sensitivity, increasing execution risk if cash conversion falters or if sector funding conditions tighten.
Only Average Returns & Margin PressureReturn metrics are middling and operating profitability is moderate, with declining EBITDA margin trends. Average ROE and margin compression constrain the company's ability to generate high returns on new investments, limiting long-term shareholder value creation absent structural margin improvements.
Shanghai Fosun Pharmaceutical (Group) Co News
SFOSF FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was $1.94 and its highest was $3.50 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is $8.68B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 41 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported $0.049 earnings per share for the quarter, beating the consensus estimate of $0.048 by <$0.001.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of $0.057 which represents an annual dividend yield of 1.76%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.05.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of $0.049 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in SFOSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.22 (15.81% Upside)
$3.22 (15.81% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
7.19%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
SFOSF Stock 12 Month Forecast
Average Price Target
$3.22
▲(15.81% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
3.58% Mutual Funds
― Other Institutional Investors
94.14% Public Companies and
Individual Investors